Hybrid Systems Based on Talc and Chitosan for Controlled Drug Release
Metadatos
Mostrar el registro completo del ítemEditorial
MDPI
Materia
Phyllosilicates Chitosan Hybrid Amiloride Drug release
Fecha
2019-11-05Referencia bibliográfica
Lima, L. C., Coelho, C. C., Silva, F. C., Meneguin, A. B., Barud, H. S., Bezerra, R. D., ... & Silva-Filho, E. C. (2019). Hybrid Systems Based on Talc and Chitosan for Controlled Drug Release. Materials, 12(21), 3634.
Patrocinador
This research was funded by FAPEPI to Caio C. Coelho for Scientific Initiation scholarshipResumen
Inorganic matrices and biopolymers have been widely used in pharmaceutical fields. They
show properties such as biocompatibility, incorporation capacity, and controlled drug release, which
can become more attractive if they are combined to form hybrid materials. This work proposes the
synthesis of new drug delivery systems (DDS) based on magnesium phyllosilicate (Talc) obtained by
the sol–gel route method, the biopolymer chitosan (Ch), and the inorganic-organic hybrid formed
between this matrix (Talc + Ch), obtained using glutaraldehyde as a crosslink agent, and to study
their incorporation/release capacity of amiloride as a model drug. The systems were characterized
by X-ray diffraction (XRD), Therma analysis TG/DTG, and Fourier-transform infrared spectroscopy
(FTIR) that supported the DDS’s formation. The hybrid showed a better drug incorporation capacity
compared to the precursors, with a loading of 55.74, 49.53, and 4.71 mg g-1 for Talc + Ch, Talc, and
Ch, respectively. The release assays were performed on a Hanson Research SR-8 Plus dissolver
using apparatus I (basket), set to guarantee the sink conditions. The in vitro release tests showed a
prolongation of the release rates of this drug for at least 4 h. This result proposes that the systems
implies the slow and gradual release of the active substance, favoring the maintenance of the plasma
concentration within a therapeutic window.